Condition
Iparomlimab and Tuvonralimab Injection clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Iparomlimab and Tuvonralimab Injection clinical trials that are recruiting, in China. By phase: Phase 2 (1), Early Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 1Country
All recruiting trials (2)
-
DC-CIK immune cell therapy combined with PD-1/CTLA-4 bispecific antibody and regorafenib for third-line advanced colorectal cancer
This treatment tries to see if combining a patient's own DC-CIK immune cells with a PD-1/CTLA-4 bispecific antibody plus regorafenib helps people with advanced colorectal cancer who have already received standard therapies.
-
QL1706 with bevacizumab plus RALOX-HAIC for liver cancer with VP3/4 portal vein tumor thrombus
This trial will test whether giving QL1706 together with bevacizumab and RALOX hepatic arterial infusion chemotherapy helps people with hepatocellular carcinoma and VP3/4 portal vein tumor thrombosis live longer or shrink tumors.
Related topics
Quick answers
How many Iparomlimab and Tuvonralimab Injection clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.